Systems-level analysis of ErbB4 signaling in breast cancer: A laboratory to clinical perspective

Molecular Cancer Research

Volumn 6, Issue 6, 2008, Pages 885-891

  Chuu, Chih Pin ^a   Chen, Rou Yu ^c   Barkinge, John L ^a   Ciaccio, Mark F ^a,b   Jones, Richard B ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA PRECURSOR; PROTEIN TYROSINE KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; BREAST CANCER; CANCER DIAGNOSIS; CELL MATURATION; DISEASE MARKER; GENE OVEREXPRESSION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LACTATION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; RNA SPLICING; BRAIN; BREAST; BREAST TUMOR; CELL PROLIFERATION; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HEART; METABOLISM; PATHOLOGY; PRENATAL DEVELOPMENT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BRAIN; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HEART; HUMANS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 50349090450     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0369     Document Type: Review

References (36)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
2. Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 2006;16:649-56.
3. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ. Expression of the c-ErbB4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998;185:236-45.
4. Wiesen JF, Young P, Werb Z, Cunha GR. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 1999;126:335-44.
5. Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 1999;147:77-88.
6. Long W, Wagner KU, Lloyd KC, et al. Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 2003;130:5257-68.
7. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995;378:390-4.
8. Zhou W, Carpenter G. Heregulin-dependent trafficking and cleavage of ErbB-4. J Biol Chem 2000;275:34737-43.
9. Cheng QC, Tikhomirov O, Zhou W, Carpenter G. Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem 2003;278:38421-7.
10. Linggi B, Cheng QC, Rao AR, Carpenter G. The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase. Oncogene 2006;25:160-3.
11. Ni CY, Murphy MP, Golde TE, Carpenter G. γ-Secretase cleavage and nuclear localization of ErbB4 receptor tyrosine kinase. Science 2001;294:2179-81.
12. Maatta JA, Sundvall M, Junttila TT, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2006;17:67-79.
13. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999;18:2607-15.
14. Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005;65:1384-93.
15. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006;439:168-74.
16. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB4 that translocates to the nucleus. J Biol Chem 2003;278:33334-41.
17. Omerovic J, Puggioni EM, Napoletano S, et al. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res 2004;294:469-79.
18. Aqeilan RI, Donati V, Palamarchuk A, et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB4 and modulate its transcriptional function. Cancer Res 2005;65:6764-72.
19. Aqeilan RI, Donati V, Gaudio E, et al. Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007;67:9330-6.
20. Pitfield SE, Bryant I, Penington DJ, Park G, Riese DJ 2nd. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res 2006;16:179-93.
21. Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000;275:8641-9.
22. Sartor CI, Zhou H, Kozlowska E, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001;11:4265-75.
23. Naresh A, Long W, Vidal GA, et al. The ERBB4/HER4 intracellular domain 80kD ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006;66:6412-20.
24. Arasada RR, Carpenter G. Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB4 intracellular domain fragment. J Biol Chem 2005;280:30783-7.
25. Abd El-Rehim DM, Pinder SE, Paish CE. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR)family in invasive breast carcinoma. Br J Cancer 2004;91:1532-42.
26. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-8.
27. Kew TY, Bell JA, Pinder SE, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer 2000;82:1163-70.
28. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7.
29. Tovey SM, Witton CJ, Bartlett JM, et al. Outcome and human epidermal growth factor receptor (HER)1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004;6:R246-51.
30. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 2000;60:1483-7.
31. Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RC, Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol 2003;56:300-4.
32. Amin DN, Perkins AS, Stern DF. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 2004;23:1428-38.
33. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005;1:2005.0008.
34. Furberg H, Newman B, Moorman P, Millikan R. Lactation and breast cancer risk. Int J Epidemiol 1999;28:396-402.
35. Beral V, Bull D, Doll R, et al. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 2002;360:187-95.
36. Jackson-Fisher AJ, Bellinger G, Shum E, et al. Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene 2006;25:5664-72.